Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06AKW
|
|||
| Former ID |
DNC005471
|
|||
| Drug Name |
N-(5-m-Tolyl-furan-2-carbonyl)-guanidine
|
|||
| Synonyms |
CHEMBL364735; N-(5-m-Tolyl-furan-2-carbonyl)-guanidine; SCHEMBL4936806
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H13N3O2
|
|||
| Canonical SMILES |
CC1=CC(=CC=C1)C2=CC=C(O2)C(=O)N=C(N)N
|
|||
| InChI |
1S/C13H13N3O2/c1-8-3-2-4-9(7-8)10-5-6-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
|
|||
| InChIKey |
BBOVVXJXVOJLSK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Regulation of actin cytoskeleton | ||||
| Thyroid hormone signaling pathway | ||||
| Salivary secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Proteoglycans in cancer | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| ErbB1 downstream signaling | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| Reactome | Hyaluronan uptake and degradation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| G Protein Signaling Pathways | ||||
| Glycosaminoglycan metabolism | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.